Glycoprotein VI
GPVI
Glycoprotein VI (GPVI) is a membrane glycoprotein unique to platelets and has been identified as a physiological receptor for collagen. Damage to a vessel wall exposes the subendothelial component collagen to platelets in the blood flow. Interaction of platelets with collagen via the receptor GPVI results in platelet activation and adhesion--the processes that are essential for thrombus formation. On the platelet surface, GPVI is present as a complex with the homodimeric Fc receptor y-chain (FcRgamma with a possible stoichiometry of two GPVI molecules and one FcRgamma dimer). When collagen binds to GPVI, a platelet activation cascade is initiated by tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif of FcRgamma and this phosphorylation induces the formation of a large complex composed from many signal-transducing proteins. In flow adhesion experiments that closely approximate physiological conditions, GPVI is essential for the formation of large platelet aggregates on collagen.
All Product Categories
-
Glycoprotein VI Related Products (26)
Related Products (26)
-
Antibodies (1)
- 1
- 2
-
Codrituzumab
0 ImagesSynonyms: GC33; RO5137382Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.
-
ACT017
0 ImagesACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke.
-
GPC3 targeting peptide 1 TFA
0 ImagesCat. No.: HY-P10888APurity: 99.40%GPC3 targeting peptide 1 TFA is a GPC3 targeting peptide, with a Kd value of 0.23 nM.
-
Anti-GPC3 Antibody (YP7)
0 ImagesCat. No.: HY-P990840
-
DOTA-GPC3 targeting peptide 2
0 ImagesDOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with Kd of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements.
-
EXP3179
0 ImagesSynonyms: Losartan Carboxaldehyde; DuP 167EXP3179 (Losartan Carboxaldehyde) is a metabolite of Losartan (HY-17512). EXP3179 binds to AT1R with an affinity of 20 nM and blocks ANGII-induced AT1R signaling, inhibiting ERK1/2 activation. EXP3179 reduces NADPH oxidase activity. EXP3179 inhibits Phenylephrine (HY-B0769)-induced aortic contraction through an endothelium-dependent, NO-dependent mechanism. EXP3179 dose-dependently inhibits type I collagen-induced platelet aggregation and activation through GPVI binding, reducing platelet adhesion to the injured site. EXP3179 lowers blood pressure in normotensive and spontaneously hypertensive rats and mice. EXP3179 can be used for research on type 2 diabetes, hypertensive heart disease, hypertension, thrombosis, and coronary artery disease.
-
GPC3 targeting peptide 2
0 ImagesCat. No.: HY-P11936CAS No.: 2244402-11-5GPC3 targeting peptide 2 is a glypican-3 (GPC3) targeting peptide that binds specifically to GPC3 with a Kd of 39.5 nM. GPC3 targeting peptide 2 can be conjugated to IRDye800 via a GGGSC linker for near-infrared fluorescence and photoacoustic imaging, with a tumor-to-adjacent liver fluorescence intensity ratio of approximately 2-fold. GPC3 targeting peptide 2 shows high specificity for immunofluorescence staining of HCC specimens. GPC3 targeting peptide 2 can be used in studies related to GPC3-targeted molecular imaging and early detection of hepatocellular carcinoma.
-
(S)-S007-1558
0 ImagesSynonyms: GPVI antagonist 1(S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM.
-
Anti-pan-Glypican Antibody (HS20)
0 ImagesCat. No.: HY-P990841Purity: 99.44%Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1 κ human antibody, targeting to human pan-Glypican. Anti-pan-Glypican Antibody (HS20) can neutralize the heparan sulfate (HS) chains on GPC3 thereby disrupting the Wnt3a-GPC3 interactions leading to blockade of the Wnt3a/β-catenin signaling. Anti-pan-Glypican Antibody (HS20) can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
-
Anti-GPC-2 Antibody (CT3)
0 ImagesCat. No.: HY-P990842Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1 κ chimeric antibody, targeting to human GPC-2. Anti-GPC-2 Antibody (CT3) reacts with tumor-associated exons 3 and 10 of glypicans-2 (GPC2). Anti-GPC-2 Antibody (CT3) can be used for the research of cancer, such as neuroblastoma.
-
Batifiban TFA
0 ImagesCat. No.: HY-125053APurity: 99.70%Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3.
-
Convulxin
0 ImagesCat. No.: HY-117123CAS No.: 37206-04-5Convulxin is a toxin found in a tropical rattlesnake. Convulxin stimulates platelet aggregation, and clusters GPVI to trigger Src family kinase activation, Fc receptor γ chain phosphorylation, and p72SYK signaling. Convulxin interacts with Dectin-2 to induce IL-10 production, activates monocytes to generate ROS and NLRP3 inflammasome-mediated IL-1β secretion, and induces mitochondrial ROS. Convulxin causes transient arterial blood pressure changes in dogs. Convulxin can be used for research related to coagulation.
-
ZW-251 Antibody
0 ImagesCat. No.: HY-P992514ZW-251 Antibody is a humanized IgG1 antibody targeting GPC3, it can be used to synthesize the ADC ZW251.
-
CAT-07
0 ImagesCat. No.: HY-P992011CAT-07 is an anti-human GPC3/Glypican 3 antibody. CAT-07 can be used for the research of cancer, such as hepatocellular carcinoma.
-
BTK-IN-50
0 ImagesCat. No.: HY-184940BTK-IN-50 is a covalent BTK inhibitor with an IC50 of 6 nM. BTK-IN-50 blocks collagen-induced platelet aggregation by inhibiting the GPVI-mediated BTK-PLCγ2-PKC signaling cascade, and attenuates CRP-XL-induced phosphorylation of BTK, PLCγ2 and PKC substrates in platelets. BTK-IN-50 can be used for research related to thrombosis.
-
SAR444200
0 ImagesCat. No.: HY-P992457SAR444200 is a nanobody targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). The KD of SAR444200 for human GPC3 is 0.023 nM, and its KD for human TCRαβ is 5.2 nM. SAR444200 mediates T cell-dependent cytotoxicity, and exhibits high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used in studies of GPC3+ solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma.
-
10P3Me
0 ImagesCat. No.: HY-P1161810P3Me is a Glypican-3 (GPC3)-targeting probe with a Ka of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions.
-
GPVI antagonist 3
0 ImagesGPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent.
-
pep-10L peptide
0 ImagesCat. No.: HY-P10949CAS No.: 1159846-95-3Pep-10L peptide is a glycoprotein VI (GPVI) antagonist with Ki values of 180, 225, and 179 μM for CPR, GPO-1, and Type 1 collagen, respectively. Pep-10L peptide has anti-thrombotic effects.
- 1
- 2
